Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Pharma Companies Announce Investments in R&D, Ongoing Clinical Trials and Financial Results - Research Report on Alnylam,



  Pharma Companies Announce Investments in R&D, Ongoing Clinical Trials and
 Financial Results - Research Report on Alnylam, Infinity, Nektar, Sequenom,
                                and Merrimack

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, August 15, 2013

NEW YORK, August 15, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Alnylam
Pharmaceuticals, Inc. (NASDAQ: ALNY), Infinity Pharmaceuticals, Inc. (NASDAQ:
INFI), Nektar Therapeutics (NASDAQ: NKTR), Sequenom Inc. (NASDAQ: SQNM), and
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Alnylam Pharmaceuticals, Inc. Research Report

On August 8, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) reported its
consolidated Q2 2013 financial results with total revenues of $8.7 million,
compared to $20.9 million in Q2 2012. R&D expenses increased by 11.5% YoY to
$24.2 million and GAAP net loss for the quarter totaled $18.2 million, or
$0.29 per share, compared to a net loss of $13 million, or $0.25 per share, in
Q2 2012. Michael Mason, Vice President, Finance and Treasurer of Alnylam said,
"Alnylam continues to maintain a solid balance sheet, ending this second
quarter with $380 million in cash. We remain on track to end 2013 with greater
than $320 million, which will continue to provide us with a strong balance
sheet to execute on our business plan and advance our RNAi therapeutics
through clinical trials and toward the market." Alnylam anticipates that its
cash, cash equivalents and total marketable securities balance will be more
than $320 million at December 31, 2013. The Full Research Report on Alnylam
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-08-13/ALNY]

Infinity Pharmaceuticals, Inc. Research Report

On August 8, 2013, Infinity Pharmaceuticals Inc. (Infinity) reported its Q2
2013 financial results with no revenue recorded for the period compared to
revenue of $21.9 million in Q2 2012. Infinity informed that Q2 2012 revenue
was mainly composed of reimbursed research and development (R&D) services
performed under a previous strategic alliance with Purdue Pharmaceutical
Products L.P. and Mundipharma International Corporation Limited. Net loss for
the quarter totaled $32.6 million or $0.68 per share against $14.7 million or
$0.54 per share in Q2 2012. R&D expenses totaled $26.1 million compared to
$28.5 million in Q2 2012, which decreased primarily due to the discontinuation
of the development of Hedgehog pathway program. For 2013, the Company
anticipates net loss in the range of $135 million to $145 million. The Full
Research Report on Infinity Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-08-13/INFI]

Nektar Therapeutics Research Report

On August 8, 2013, Nektar Therapeutics (Nektar) reported its Q2 2013 financial
results with revenue of $33.9 million compared to $23.7 million in Q2 2012.
Net loss for the quarter totaled $42.7 million or $0.37 loss per share,
compared to $34.3 million or $0.30 loss per share in Q2 2012. R&D expenses
totaled $52.2 million compared to $33.2 million in Q2 2012. According to
Nektar, the increase in R&D expenses reflected the costs of different clinical
trials. Howard W. Robin, President and CEO of Nektar said, "I am very pleased
with Nektar's performance this year. We are on track to report high-level
results from the Phase 2 efficacy study of NKTR-181 in chronic pain patients
this summer. Finally, we recently completed enrollment in our Phase 3 study of
NKTR-102 ahead of schedule." The Full Research Report on Nektar Therapeutics -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-08-13/NKTR]

Sequenom Inc. Research Report

On August 1, 2013, Sequenom Inc. (Sequenom) and CombiMatrix Corp. jointly
announced that the Sequenom Center for Molecular Medicine LLC and CombiMatrix
have entered into a collaboration agreement to market chromosomal microarray
analysis (CMA) testing services to widen and confirm the results of
noninvasive, prenatal testing (NIPT) to physicians and their patients. Bill
Welch, President and COO of Sequenom, Inc. said, "The MaterniT21 PLUS test is
the premier, noninvasive prenatal test on the market today, and for an
important group of patients a chromosomal microarray test can be a significant
adjunct for a comprehensive prenatal analysis. CombiMatrix specializes in CMA
and their technology helps further expand our product offering in the growing
prenatal genetic testing marketplace." The Full Research Report on Sequenom
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.investorsreports.com/report/2013-08-13/SQNM]

Merrimack Pharmaceuticals, Inc. Research Report

On August 8, 2013, Merrimack Pharmaceuticals, Inc. (Merrimack) reported its Q2
2013 financial results with collaboration revenues of $18.5 million compared
to $12.1 million in Q2 2012. Net loss for the quarter totaled $30.3 million or
$0.31 per share compared to net loss of $20.1 million or $0.22 per share in Q2
2012. R&D expenses totaled $42.5 million compared to $28.8 million in Q2 2012.
Merrimack informed that the increase in R&D expenses is primarily attributable
to ongoing clinical trials. Robert Mulroy, President and CEO of Merrimack
said, "We are pleased with a strong quarter of progress advancing our pipeline
of six novel therapeutic candidates. We remain on track for a robust set of
milestones in the months ahead and we remain focused on our goal of delivering
transformative therapies to patients to dramatically improve cancer outcomes."
The Full Research Report on Merrimack Pharmaceuticals, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-08-13/MACK]

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

http://www.InvestorsReports.com

SOURCE Investors' Reports

Contact: Kristi Saunders, +1-315-982-6420 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement